Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , may provide a promising development for obesity loss . Early human investigations have indicated impressive reductions in body fat , potentially surpassing other body composition therapies . Nevertheless , more assessment is necessary to fully understand